Belief is your safe passage—the door through which all healing resides. Why? Because your perception is your reality. Believing in the science of TMS ( tension myositis syndrome) sends a message of ...

The U.S. Food and Drug Administration has approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx ...

The US Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or ...

The FDA's approval of the non-addictive painkiller Journavx last week marked a milestone in the field of pain management. Why ...

Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...

The new drug will carry a list price of $15.50 per pill, making it many times more expensive than comparable opioids.

A massive stride has been made in the pain medication industry. The U.S. Food and Drug Administration (FDA) announced Thursday its approval of a non-opioid treatment for moderate to severe acute pain ...

The Food and Drug Administration announced Thursday its approval of suzetrigine, the first new painkiller greenlit by the ...

It's the first new pharmaceutical approach to treating pain in over 20 years, designed to eliminate risks of addiction and ...

Created by Johns Hopkins researchers, EpiScalp could significantly reduce false positives and spare patients from medication side effects, driving restrictions, and other quality-of-life challenges ...

When a child develops a brain tumor, early diagnosis is essential. Alan Cohen, M.D., director of pediatric neurosurgery at Johns Hopkins Children’s Center, shares the most common signs and symptoms ...

The brain interprets these sensory cues to understand what’s going on outside and inside the body. This allows a person to use their body to interact with their surrounding environment and ...